Network Pharmacology Combined with Mendelian Randomization Analysis to Identify the Key Targets of Renin-angiotensin-aldosterone System Inhibitors in the Treatment of Diabetic Nephropathy
Overview
Affiliations
Background: Diabetic Nephropathy (DN) is one of the microvascular complications of diabetes. The potential targets of renin-angiotensin-aldosterone system (RAAS) inhibitors for the treatment of DN need to be explored.
Methods: The GSE96804 and GSE1009 datasets, 729 RAAS inhibitors-related targets and 6,039 DN-related genes were derived from the public database and overlapped with the differentially expressed genes (DN vs. normal) in GSE96804 to obtain the candidate targets. Next, key targets were screened via the Mendelian randomization analysis and expression analysis. The diagnostic nomogram was constructed and assessed in GSE96804. Additionally, enrichment analysis was conducted and a 'core active ingredient-key target-disease pathway' network was established. Finally, molecular docking was performed.
Results: In total, 60 candidate targets were derived, in which and were screened as the key targets and had a causal association with DN as the protective factors ( < 0.05, OR < 1). Further, a nomogram exhibited pretty prediction efficiency. It is indicated that Benadryl hydrochloride might play a role in the DN by affecting the pathways of 'cytokine cytokine receptor interaction', etc. targeting the . Moreover, might be involved in 'ECM receptor interaction', etc. for the effect of NSAID, captopril, chlordiazepoxide on DN. Molecular docking analysis showed a good binding ability of benadryl hydrochloride and , NSAID and . , , and are causally associated with acute kidney injury.
Conclusion: and were identified as key targets for RAAS inhibitors in the treatment of DN, which might provide some clinical significance in helping to diagnose and treat DN. Among the targets of RAAS inhibitors, PTGS2, ITGA4 and ANPEP have a causal relationship with acute kidney injury, which is worthy of further clinical research.
Huang Q, An C, Tang S, Leng Y, Zhang Y, Wan B Front Endocrinol (Lausanne). 2024; 15:1444808.
PMID: 39735650 PMC: 11671268. DOI: 10.3389/fendo.2024.1444808.